Gynecol Oncol 2019 Sep
Defining the survival benefit of adjuvant pelvic radiotherapy and chemotherapy versus chemotherapy alone in stages III-IVA endometrial carcinoma.
Related Questions
New answer by Radiation Oncologist at David Geffen School of Medicine at UCLA (October 16, 2020)
This is an excellent question that speaks to the numerous recent developments, and ongoing controversies, regarding the ideal adjuvant approach to stage III endometrial cancer...
Planning carboplatin/taxol/trastuzumab. Cervical stromal invasion on path. Looking for pelvic vs brachy and timing with chemotherapy.
New answer by Radiation Oncologist at David Geffen School of Medicine at UCLA (April 30, 2021)
Stage III (particularly IIIC) and serous histology are both risk factors for distant failure. In combination, the patient is at an even higher risk. Therefore, I would priorit...